Quick Reference (Pre-Interview Pull-Up)
The consulting objection is five fears wearing one label. Only one is a genuine gap. The other four have portfolio-grounded answers.
Your real gap: You did not own post-launch entropy. Team churn, roadmap politics, quality decay, second-version decisions. Do not pretend otherwise. See Sub-Fear #1 for the honest response.
Your central claim: Three products you built at BCG DV are independently confirmed live in 2026. A fourth organization is operationally active. Systems that survive the departure of their designer are harder to build than systems that depend on their designer staying. You have proof of the first kind.
| Sub-Fear | Lead Evidence | Confidence |
|---|---|---|
| No post-launch ownership | Honest gap + formation-under-ambiguity reframe | Use with caution |
| Advisory, not operational | BCG DV equity model + production metrics + Alibaba | High |
| Process-heaviness | Equinox+ 0→MVP in 3 months; Red Cross constraint dissolution | High |
| No skin in the game | Products still live; Allē reversion story | High |
| Short-tenure pattern | 12-month Thermo Fisher, 6 partners, 9 sites, $20M+ annual margin recovery | Moderate |
Hits hardest at: Late-stage enterprise design orgs, mature product companies with long planning cycles. Heaviest for Head of Design roles where sustained org ownership is the job.
Barely registers at: Growth-stage 0→1 companies, AI-native companies (different objection entirely), Principal IC roles where craft judgment matters more than tenure pattern.
Before Anyone Asks
This objection has a version that lives in your head before it ever comes out of an interviewer's mouth. You know the gap is real. You know you left before the hard middle. That internal doubt is the actual risk, because it makes every external version of the question feel like confirmation rather than something you can answer. This dossier is designed to resolve it for you before you walk into the room. The goal is precise, honest language for what you did and did not do, so the doubt stops leaking into your delivery.
Lead with the gap. Earn the right to reframe. Let the evidence close.
Five Fears, One Label
When an interviewer says "Your background is consulting" or "Help me understand how this translates to an in-house role," they are voicing up to five separate fears. They may not know which one matters most to them until you answer.
Answer only the surface question and the hidden fears stay intact, coloring every subsequent evaluation. Answer the wrong sub-fear and you sound defensive about something they weren't worried about.
The order below is deliberate. Start with the gap. Earn the right to reframe.
Sub-Fear #1: She Didn't Own Post-Launch Entropy
"What happens after you ship? Have you ever lived with a product through its second year?"
This is the real gap. Do not paper over it.
BCG DV engagements were venture-formation builds. You shipped production systems, but the documented engagement windows (3 months for Equinox+, 12 months for Thermo Fisher) mean you were not the person managing year-two entropy. The feature that breaks at scale. The PM who reprioritizes your roadmap. The slow quality decay that happens when nobody is watching. An interviewer who has lived through that will hear a false note instantly, and the false note will cost you more than the gap itself.
Say this:
"You're right that I didn't own year-two entropy at BCG DV. What I owned was the formation problem. Building systems from zero under ambiguity, with nothing to inherit, no established team norms, and a hard ship date. The test of whether I built well is whether those systems survived my departure. Three of them are still live. Thermo Fisher's mySupply is operationally deployed across their pharma services division today. Equinox+ is actively updated. Allē has 30 million members. I'm not claiming formation is harder than sustained ownership. They're different problems. But formation that produces durable systems is the version most people never get tested on."
Confidence: Use with caution. This reframe is honest and defensible, but it works only if you hold the peer frame. The moment you imply formation is superior to sustained ownership, you lose the interviewer who has spent three years keeping a product alive through organizational chaos.
Reference-safety check: Would a former BCG DV colleague repeat this version? Yes, because it concedes the gap before reframing. Would a hiring manager who checks with someone at Thermo Fisher hear a consistent story? The platform is confirmed live. The claim holds.
Sub-Fear #2: Advisory, Not Operational
"Consulting is recommendations and decks. Did you actually ship?"
You can answer this one directly. BCG Digital Ventures was structurally distinct from traditional strategy consulting. The model was venture building: BCG DV assembled designers, engineers, and product managers as an embedded founding team, built production products, and took equity stakes in the resulting businesses. Fees were at risk against shipping milestones. Engineers, product, and design teams ideated and conducted user research together from the start of each venture. There was no siloed handoff because, at the end of the day, they were building a product together.
Say this:
"The firm took equity stakes in the ventures we built. Fees were at risk against shipping milestones. I was embedded as the design lead on a founding team building a production product. Thermo Fisher mySupply launched across 9 manufacturing sites with 6 pharma partners. Red Cross deployed nationally under federal oversight. Alibaba was international production deployment at enterprise scale. These shipped into real operations with real users and real consequences."
Do not say "BCG DV wasn't really consulting." That invites a definitional argument you cannot win. Describe what happened. Production evidence makes the employer logo irrelevant.
Confidence: High. The structural model is documented. The production metrics are published. BCG DV launched more than 200 digital businesses before its integration into BCG X in December 2022.
Sub-Fear #3: Process-Heaviness
"We move fast here. Consulting backgrounds tend to bring a lot of process."
Lead with Equinox+. Zero to MVP in three months. 4.8-star launch rating. 600K+ members. That timeline does not leave room for process theater.
Say this:
"Equinox+ went from zero to MVP in three months with a 4.8-star launch. My default is to dissolve constraints into the product so they don't become a separate process layer. At Red Cross, federal disaster-relief compliance had to be airtight. The case management system unified disbursement tracking and compliance reporting into a single workflow on Salesforce SLDS, so caseworkers weren't switching between a compliance process and a service-delivery process. The oversight was built into the architecture. It never became a gate that slowed the team down. That's the skill: making the constraint invisible to the people who need to ship."
This reframe covers both the speed concern and the related worry that you'll introduce heavyweight compliance rituals. The constraint-dissolution pattern is your strongest evidence that regulated-domain experience produces faster teams.
A note on verbal elaboration: If the interviewer presses on the Red Cross example, be prepared to walk through the specific compliance requirement that became a product feature rather than a process gate. The unified case management architecture is the anchor. If you can describe the caseworker's experience of compliance-as-workflow rather than compliance-as-checkpoint, that's the detail that lands.
Confidence: High. Timeline and rating are published portfolio evidence. The constraint-dissolution pattern is demonstrated across Red Cross (federal oversight) and Thermo Fisher (pharma regulatory).
Sub-Fear #4: No Skin in the Game
"In consulting, you can walk away. In-house, you live with your decisions."
The Allē story answers this better than any argument you could construct.
Allē, the Allergan/AbbVie loyalty platform, is still live with 30 million+ members. In late 2024, AbbVie attempted to replace the original program with a redesigned loyalty structure called "Allē Enhancements." Providers rejected the replacement as too complex to integrate into their practices, negatively impacting market share and inventory levels. In January 2025, AbbVie reverted to the original program. Providers responded favorably, with encouraging early indicators for sales and market share recovery. The system you designed outlasted an internal attempt to replace it.
Say this:
"Staying is one form of accountability. Building something durable enough that it doesn't need you is another. Allē is the most striking example. AbbVie tried to replace the loyalty program with a redesigned version, and providers rejected the replacement as too complex. They reinstated the original. I wasn't in the room for that decision. But the system I helped build was the one they went back to."
Important boundary: Do not claim you designed the specific elements that survived the reversion. Claim only what's factual: the program architecture you worked on is the one that's currently live, and an attempted replacement failed. Let the interviewer draw the inference.
Confidence: High. Product live status is independently confirmed. The reversion is documented in industry press. AbbVie's own earnings communications reference the reinstatement.
Sub-Fear #5: Short-Tenure Pattern
"I see a lot of 6-to-12-month engagements. How do I know you'll stay?"
The weakest objection on its face, but it maps to a pattern interviewers have been burned by before. Your answer needs texture, not just logic.
The Thermo Fisher engagement was 12 months. That number alone sounds short until you describe what 12 months contained: a supply-chain platform built across 9 manufacturing sites with 6 pharma partners, generating $20M+ in annual margin recovery with an 83% internal rate of return. That is deep operational integration with a complex multi-stakeholder system where the handoff had to work because the platform was load-bearing for real pharmaceutical supply chains the day you walked away.
Say this:
"The Thermo Fisher build was 12 months. In that window, we shipped a supply-chain platform across 9 manufacturing sites with 6 pharma partners, generating $20M+ in annual margin recovery with an 83% internal rate of return. It's still operationally deployed today, referenced in their 2026 industry communications. The engagement length reflected the scope, not a preference for short tenure. I stayed until the system was operational and the handoff was clean. I'm looking for a problem where the complexity earns years of attention. That's what I'm evaluating in this conversation too."
End with the forward-looking statement, but tie it to the specific company's problem. Generic intent sounds like interview polish. Specific intent sounds like conviction. Before you walk in, know what about their product domain would hold your attention for years, and say that.
Confidence: Moderate. The Thermo Fisher evidence is strong. The forward-looking claim depends on the interviewer believing your stated intent, which is why specificity about their problem matters more than the general frame.
Tier Map: Where This Objection Lives
By Company Type
Primary risk — lead with Sub-Fears #1 and #2 preemptively. Late-stage enterprise design orgs. Mature product companies with long planning cycles. These companies have lived through post-launch entropy and they value sustained ownership. Their postings signal this with language like "experience scaling products post-launch" and "long-term product ownership." Address the consulting background before they raise it. Allē and Thermo Fisher are your strongest material here. Alibaba's enterprise-scale deployment adds credibility in this tier.
Moderate risk — address if raised, don't lead with it. Growth-stage companies in regulated or complex domains. Headway's Design Director posting asks for "5+ years leading a design team for complex B2B SaaS platforms" and "experience with hyper-growth startups (Series C+)." The consulting skepticism is embedded in the requirements, not stated explicitly. Your regulated-domain evidence (Red Cross, Thermo Fisher) maps directly to their operating reality. Lead with domain fit. Let the consulting question dissolve rather than defending against it.
Low risk — likely a non-issue. Growth-stage fintech and high-velocity companies that explicitly value output over pedigree. Ramp's Director posting stated: "We care less about where you trained and more about what you've built." The consulting label dissolves the moment you show production evidence. Don't raise it.
Near-zero risk — different objection entirely. AI-native companies (Anthropic, OpenAI). Their skepticism is about whether you have hands-on judgment near model behavior, whether you've built with probabilistic systems, whether your AI work is production or portfolio theater. The consulting question won't come up. Your Agentic Labs work (three live agents built solo, trust-calibration architecture) is the bridge to AI-native builder credibility. Their concern is specific: can you design for systems whose outputs you cannot fully predict? The consulting label is irrelevant to that evaluation.
By Role Type
The consulting objection hits differently depending on what the role actually requires.
Head of Design: Highest skepticism. This role is about sustained organizational ownership. The interviewer is imagining you building a team, losing half of it in a reorg, rebuilding, fighting for headcount through two planning cycles. Your formation evidence is strong but the entropy gap is most visible here. Lead with Sub-Fear #1's honest concession. You need the interviewer to believe you want the sustained problem, not just the formation problem.
Design Director (embedded in product org): Moderate skepticism. Player-coach roles care about craft judgment and shipping velocity. Headway's posting explicitly asks for someone who can "own strategic design initiatives hands-on as a player-coach." Your BCG DV experience maps well to this operating mode. The consulting concern is present but secondary to production evidence.
Principal IC / Staff+: Lowest skepticism. These roles value depth of craft judgment and system-level thinking over tenure pattern. The evaluation centers on whether your design decisions hold under pressure. Your portfolio answers that directly.
Calibrating the "Products Still Live" Claim
You have been saying "four products still live." Here is the honest version, calibrated to what's independently verifiable as of July 2026:
- Thermo Fisher mySupply: Confirmed live. Patheon's fact-sheet page updated April 2026. Referenced in a June 2026 industry interview as an active customer-facing platform.
- Equinox+: Confirmed live. App updated June 8, 2026. Available on mobile, web, Apple TV, and Roku. Has evolved materially from launch architecture.
- Allē: Confirmed live. App updated May 29, 2026. Original program reinstated January 2025 after failed replacement attempt.
- Red Cross: Organization operationally active, responding to 60,000+ disaster responses annually. Specific platform status cannot be independently confirmed from public sources. Normal for internal enterprise systems at nonprofits, but do not overclaim.
Say "three products I built are independently confirmed live today; a fourth organization is operationally active with the disaster-relief function I designed for." Don't say "all four are still running exactly as I built them." You don't know that. An interviewer who checks will find the same ambiguity you're looking at.
When the Consulting Label Is Masking a Different Question
Sometimes the interviewer says "consulting background" but means something else entirely.
If the follow-up questions focus on team size, hiring plans, and org structure, the concern is scaling capability. That's a different dossier with different evidence. Do not answer the consulting question when the scaling question is what's actually on the table.
If the follow-up questions focus on AI tooling, model behavior, and evaluation frameworks, they're asking about technical depth. Your Agentic Labs work and the trust essay answer that. The consulting frame is a convenient container for a concern that has nothing to do with BCG DV.
If the follow-up questions focus on "how would you handle a PM who disagrees with your direction" or "tell me about a time you lost a prioritization battle," they're testing for organizational durability. That's the post-launch entropy gap from Sub-Fear #1, wearing different clothes. Go back to the honest concession and the formation reframe.
The consulting objection reduces to a durability question. Did you build things that lasted, or things that looked good in a presentation?
You have an answer most in-house designers never get to give. Your systems were tested by your absence. You left, and the products kept running. One of them survived an active attempt to replace it.
That evidence is yours. Use it precisely.
- Backdoor references are escalating: Companies like Zapier now require live reference conversations before offers, with senior roles triggering up to 10 calls including off-book references, which means every reframe in this dossier must survive repetition by someone who isn't you.
- Ramp's origin-agnostic hiring language: Their Director, Product Design posting explicitly stated "we care less about where you trained and more about what you've built", making it the clearest signal that consulting skepticism is a non-issue at high-velocity fintech companies that evaluate on production output.
- Thermo Fisher mySupply confirmed operational: A PharmTech interview from approximately June 2026 quotes a Thermo Fisher representative describing mySupply as an active customer-facing transparency platform used in live partner discussions, which is the strongest independent corroboration of the "products still live" claim.
- AI-native roles test different anxieties: Anthropic's Applied AI posting asks candidates to "learn how work actually gets done, encode that understanding into products, evaluations, and workflows, and measure success by real-world adoption", confirming that the consulting question dissolves at AI-native companies and the real filter is production depth with probabilistic systems.